U.S. Fertility Innovation Fund invests in Evvy
Funding Provisional 86% confidence first seen
Evvy (Allora Health Inc.) closed a $40 million Series B round that included investment from the U.S. Fertility Innovation Fund, alongside Catalio Capital Management (which led the round) and other participants such as Rethink Impact, Muse Capital and Alumni Ventures. The coverage says the new capital will be used to validate AI-enabled diagnostic and care models, beginning with fertility-focused care. This matters because it expands funding behind precision, data-driven women’s health diagnostics and aims to translate vaginal microbiome insights into more personalized treatment pathways for fertility and related conditions.
The deal
Evvy $40M Series B · announced 15 Sep 2026
Investors Alumni Ventures Catalio Capital Management
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Evvy, a women’s health AI startup, closed a $40 million Series B round that included the U.S. Fertility Innovation Fund, with Catalio Capital Management leading the round. According to the coverage, Evvy plans to use the capital to validate new AI-enabled diagnostic and care models, starting with fertility-focused care.
- Why it matters
- This financing gives Evvy more resources to expand AI-driven diagnostics and care in women’s health, particularly in fertility, which could increase competition and partnership activity in precision reproductive health. For decision-makers in healthcare, diagnostics, and digital health, the round signals that investors are backing platforms that combine patient data, microbiome insights, and care pathways rather than standalone testing alone.
- Evidence
- The coverage comes from a single SiliconANGLE article reporting that Evvy raised $40 million, named the participating investors, and stated the funding will support validation of AI-enabled diagnostic and care models beginning with fertility-focused care. The same report also cites company-stated performance claims on diagnosis rates and recurrence reduction, but no independent validation is described in the provided coverage.
- What remains uncertain
- Open questions include how much of the round came specifically from the U.S. Fertility Innovation Fund, what regulatory or clinical validation standards Evvy’s AI models must meet, and whether the reported diagnostic and recurrence outcomes will hold up in broader independent studies. The coverage does not provide external clinical verification, commercial traction details, or timelines for fertility-focused product rollout.
- Monitor next
- Watch for Evvy to publish clinical validation results or announce fertility-care partnerships that show how the new funding is being converted into deployable AI diagnostic offerings.
Analytical support, not advice — assumptions and open questions stated above.